Skip to main content
. 2022 Sep 21;2022:9388813. doi: 10.1155/2022/9388813

(a) Results from univariate analyses

ALZ or CLA 0.27
(0.06, 1.28)
. . . 1.29
(0.24, 6.90)
1.07
(0.41, 2.80)
.
0.83
(0.30, 2.27)
Anti-CD20 agents 3.11
(0.75, 12.94)
2.56
(0.91, 7.20)
0.70
(0.17, 2.98)
2.86
(1.21, 6.77)
1.32
(0.84, 2.07)
0.77
(0.18, 3.24)
2.40
(0.43, 13.3)
2.90
(0.70, 12.03)
DMF 0.82
(0.15, 4.52)
0.23
(0.03, 1.64)
1.33
(0.19, 9.47)
0.55
(0.13, 2.43)
0.25
(0.03, 1.78)
1.71
(0.51, 5.69)
2.07
(0.94, 4.54)
0.71
(0.15, 3.45)
FNG 0.28
(0.05, 1.53)
1.61
(0.29, 8.84)
0.74
(0.34, 1.60)
0.30
(0.05, 1.66)
0.62
(0.17, 2.17)
0.74
(0.31, 1.82)
0.26
(0.05, 1.32)
0.36
(0.12, 1.08)
NTZ 5.85
(0.81, 42.25)
1.97
(0.85, 4.56)
1.09
(0.15, 7.94)
2.62
(0.77, 8.83)
3.17
(1.38, 7.25)
1.09
(0.22, 5.47)
1.53
(0.52, 4.50)
4.25
(1.34, 13.46)
No DMT 0.39
(0.17, 0.92)
0.19
(0.03, 1.34)
1.17
(0.45, 3.02)
1.41
(0.92, 2.17)
0.49
(0.11, 2.06)
0.68
(0.32, 1.45)
1.90
(0.82, 4.38)
0.45
(0.19, 1.02)
Platform therapy 0.45
(0.10, 1.99)
0.59
(0.11, 3.33)
0.72
(0.17, 3.01)
0.25
(0.03, 1.78)
0.35
(0.07, 1.70)
0.96
(0.19, 5.00)
0.23
(0.04, 1.15)
0.51
(0.12, 2.18)
TRF